Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin.
Immunotoxins are hybrid molecules which combine the exquisite selectivity of monoclonal antibodies with the potent toxicity of protein toxins. An immunotoxin was constructed by linking a murine monoclonal antibody against the human transferrin receptor (TR) to the plant toxin, ricin. The cytotoxic activity of the anti-TR-ricin immunotoxin was tested in vitro and demonstrated highly potent and cell type-specific killing of cells derived from human glioblastoma, medulloblastoma, and leukemia. The anti-TR-ricin immunotoxin killed more than 50% of "target" cells at a concentration of 5.6 X 10(-13) M after an 18-hour incubation with the ionophore, monensin. This potency exceeds that of any other anti-TR immunotoxin reported in the literature. When the activity of the anti-TR-ricin immunotoxin against "target" tumor-derived cells was compared with the immunotoxin's activity against "non-target" cells, it could be predicted that a selective toxicity of anti-TR-ricin immunotoxin between tumor cells and normal brain was more than 150- to 1380-fold. Solid-phase indirect radioimmunoassay techniques were used to demonstrate significantly higher levels of TR in the glioblastoma- and medulloblastoma-derived cell lines, as well as in surgical tissue samples of medulloblastoma and glioblastoma, as compared to normal brain. Immunotoxins targeted to the TR may possess sufficient specificity to be of therapeutic importance, particularly to treat neoplastic disease of the central nervous system involving compartments (such as intrathecal, intraventricular, or cystic) where delivery of immunotoxins to tumor would not require transvascular transport.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000276:immunology / Q000628:therapy*; D002460:Cell Line; D003602:Cytotoxicity, Immunologic; D005909:Glioblastoma / Q000628:therapy; D006801:Humans; D000922:Immunotoxins / Q000276:immunology / Q000627:therapeutic use*; D007942:Leukemia, Experimental / Q000628:therapy; D008223:Lymphoma / Q000628:therapy; D008527:Medulloblastoma / Q000628:therapy; D051379:Mice; D011990:Receptors, Transferrin / Q000276:immunology / Q000627:therapeutic use*; D012276:Ricin / Q000276:immunology / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D000922:Immunotoxins; D011990:Receptors, Transferrin; D012276:Ricin